N/A N=19 mHealth for Patient Self-Management of Opioid Use Disorder
Opioid-use Disorder
Primary: Usability Score — 89.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
Opioid Medication Assisted Treatment
Primary: Number of Patients Within Participating Sites With OUD Initiating MOUD During the Implementation Facilitation Period in Implementation Sites. This Will be Compared to…
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
N/A N=65 Harnessing Digital Health to Understand Clinical Trajectories of Opioid Use Disorder
Opioid-use Disorder
Primary: Smartphone Sensor Data — 94.2 mean percentage of days
N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
N/A N=105 Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
Opioid-use Disorder
Primary: Adherence to Medication Assisted Treatment (MAT) — 32; 17 Participants
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
N/A N=254 Collaborating to Heal Addiction and Mental Health in Primary Care
Opioid-use Disorder · Mental Health Disorder
Primary: Opioid Use Other Than As Prescribed — 3.92; 0.72 Days — p=<0.001
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=52 Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Post Traumatic Stress Disorder · Opioid-use Disorder
Primary: Change in Posttraumatic Stress Disorder (PTSD) Symptom Severity — -11.4; -12.8; -18.3 Score on a scale
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=16 Usability Testing for the Reward-based Technology to Improve OUD Treatment
Opioid-use Disorder · Contingency Management · Medication for Opioid-use Disorder
Primary: OARSCM Usability - Phase 1 Usability — 12 Participants
Phase 1 N=60 An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment
Opioid Use Disorder · Chronic Pain
Primary: Retention — 3.7; 3.6 number of sessions attended
Phase 3 N=20 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Substance-Related Disorders · Substance Use Disorders · Substance Abuse, Intravenous
Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale
N/A N=171 Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
Opioid-use Disorder
Primary: Number of Participants With Retention in Medication Treatment for OUD — 46; 51 Participants — p=0.94
N/A N=240 Prevention of OUD: The HOME Project (Housing, Opportunities, Motivation and Engagement)
Substance Use
Primary: Frequency (% Days) of Opioid Use in Prior 3 Months — 0; 0 % days opioid use
N/A N=45 We The Village Family Support Study
Community Reinforcement And Family Training · Family Health · Substance-Related Disorders
Primary: Treatment Entry: IP Treatment Status — 10; 8; 6 count of participants — p=0.02578184
N/A N=5,047 Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD
Clinical Decision Support · Buprenorphine · Opioid-use Disorder
Primary: Count of Initiating BUP in the ED With Referral for Ongoing MOUD With User-centered CDS Compared With Usual Care — 347; 271 Participants — p=0.58
N/A N=11,197 Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)
Opioid-use Disorder
Primary: Number of Patients With OUD Diagnosis — 36; 24 participants — p=<0.05
Early Phase 1 N=7 Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine
Addiction
Primary: Agitation Calmness Evaluation Scale (ACES) — 4; 4; 4; 4.07 score on a scale
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days
N/A N=88 Comparing Two Training Methods for Opioid Wizard
Opioid-use Disorder · Opioid Dependence · Attitude of Health Personnel
Primary: Difference, Disdain, and Blame Scales — 4.1; 4.3 score on a scale — p=.63
N/A N=228 Treatment of Pregnant Women With OUD
Opioid-use Disorder
Primary: Treatment Engagement — 78; 64; 109; 92 Participants — p=0.5340
Phase 2 N=25 Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Opiate Substitution Treatment · Opioid-Related Disorders
Primary: Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) — -5.00; -13.34 score on a scale
Phase 2 N=10 An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
Opioid-use Disorder
Primary: Sublocade Induction — 10 Participants
N/A N=115 Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
Opioid Use · Opioid-use Disorder · Suicide
Primary: Number of Participants With CSSRS Completion on the Same Day or in the 14 Days Following Any Outpatient Visit — 14; 8 Participants